Boston Scientific (BSX) EBITDA (2009 - 2026)

Boston Scientific's EBITDA history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, EBITDA rose 19.54% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $3.8 billion (up 33.13% YoY), while the FY2025 annual figure was $3.6 billion, up 38.8% from the prior year.
• EBITDA came in at $1.1 billion for Q1 2026 at Boston Scientific, up from $825.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.1 billion in Q1 2026 to a low of $358.0 million in Q3 2022.
• A 5-year average of $665.2 million and a median of $675.0 million in 2024 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 123.33% in 2022 and fell as far as 7.49% in 2022.
• Boston Scientific's EBITDA stood at $402.0 million in 2022, then soared by 45.27% to $584.0 million in 2023, then gained by 15.58% to $675.0 million in 2024, then advanced by 22.22% to $825.0 million in 2025, then soared by 33.45% to $1.1 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $1.1 billion, $825.0 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison